

Cost-effectiveness of CERAMENT® G in the United States presented at ISPOR conference

BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announces that a cost-effectiveness analysis of CERAMENT G was presented at the leading health economic conference ISPOR Europe 2022 on 7 November 2022. The analysis shows that a single-stage protocol with CERAMENT G is a cost-effective strategy to treat bone infection compared to the standard of care in the United States.

When using CERAMENT G instead of antibiotic-loaded PMMA beads, cost reductions are estimated to be USD27,943 on average per patient due to less surgeries and intra- and post-surgical complications. The analysis also shows improved patient quality of life. Greater cost reductions were found compared to other multi-stage protocols to manage bone infection.

The study is based on a health economic model developed to compare healthcare costs benefits from a third-party payer perspective between CERAMENT G and two groups of multi-stage protocols, one of which included antibiotic-loaded PMMA beads. The model simulated one million patients over a two-year horizon from the time they received surgery for bone infection.

“Reducing the number of surgeries in the management of bone infection is a win for patients, hospitals, and society,” said Emil Billbäck, CEO of BONESUPPORT.

About ISPOR

The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) meeting is arranged by the Professional Society for Health Economics and Outcomes Research on 6-9 November 2022 in Vienna, Austria. ISPOR Europe 2022 is the leading European conference for Health Economics and Outcomes Research (HEOR).

The poster presentation is published on the ISPOR [website](#).

Press Release
07 November 2022 16:00:00 CET



For more information contact:

BONESUPPORT Holding AB
Emil Billbäck, CEO
+46 (0) 46 286 53 70

Håkan Johansson, CFO
+46 (0) 46 286 53 70
ir@bonesupport.com

Cord Communications
Charlotte Stjerngren
+46 (0) 708 76 87 87
charlotte.stjerngren@cordcom.se
www.cordcom.se

About BONESUPPORT™

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs. BONESUPPORT's bone graft substitutes are based on the patented technology platform **CERAMENT**. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 213 million in 2021. Please visit www.bonesupport.com for more information.

BONESUPPORT and CERAMENT are **registered trademarks** of BONESUPPORT AB.

Attachments

[Cost-effectiveness of CERAMENT® G in the United States presented at ISPOR conference](#)